Table I.
Demographic features and clinical staging of the groups used for the evaluation of PAT-SC1 effect and PAT-SC1 antigen expression as a diagnostic/prognostic marker.
| Group 1 CD55PAT-SC1-positive (prior to 1997) (n=93) |
Group 2 CD55PAT-SC1-negative (prior to 1997) (n=33) |
Group 3 CD55PAT-SC1-positive (after 1997) (n=51) |
|
|---|---|---|---|
| Age (years) mean ± SD | 63.7±11.5 | 64.4±12.0 | 62.6±12.6 |
| Gender n (%) | |||
| Female | 32 (34.4) | 11 (33,3) | 26 (51,0) |
| Male | 61 (65.6) | 22 (66.7) | 25 (49.0) |
| Histological stage (%) | |||
| Adenocarcinoma (intestinal type) | 47 (50.5) | 18 (54.5) | 9 (17.6) |
| Signet ring cell carcinoma (diffuse type) | 43 (46.2) | 15 (45.5) | 36 (70.6) |
| Other | 3 (3.2) | 6 (11.8) | |
| UICC staging (%) | |||
| 1A | 9 (9.7) | 5 (15.2) | 10 (19.6) |
| 1B | 8 (8.6) | 5 (15.2) | 10 (19.6) |
| 2 | 15 (16.1) | 7 (21.2) | 11 (21.6) |
| 3A | 20 (21.5) | 8 (24.2) | 3 (5.9) |
| 3B | 10 (10.8) | 2 (6.1) | 4 (7.8) |
| 4 29 | (31.2) | 5 (15.2) | 12 (23.5) |
| X | 2 (2.2) | 1 (3.0) | 1 (2.0) |
| Residual tumour classification (%) | |||
| R0 | 53 (57.0) | 26 (78.8) | 35 (70.0) |
| R1 | 11 (11.8) | 3 (9.1) | 2 (4.0) |
| R2 | 29 (31.2) | 4 (12.1) | 13 (26.0) |
UICC, Union Internationale Contre le Cancer.